Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
Status:
Recruiting
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
This is a Phase 3, randomized, double-blind, placebo-controlled study evaluating DPI-386
Nasal Gel versus placebo. Approximately 500 subjects will be randomized 1:1 (250 DPI 386
Nasal Gel/250 matching Placebo Nasal Gel) are planned to be enrolled.